Gross dollar volume rose 9% in the second quarter, while purchase volume was up 10% from one year ago. Mastercard's resilient business model hasn't just led to immense financial strength -- it's also ...

Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Fox News' Bryan Llenas reports from the picket line at Red Hook Terminal in New York on the union's demands and impact of the ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

The S&P 500 Index ( $SPX) ( SPY) today is down by -0.38%, the Dow Jones Industrials Index ( $DOWI ) ( DIA) is down by -0.66%, and the Nasdaq 100 Index ( $IUXX) ( QQQ) is down by -0.25%.

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...